

## Special Issue

# Radiomics and Molecular Biology in Glioma: A Synergistic Approach

### Message from the Guest Editors

Glioma, a malignant brain tumor, presents significant challenges in diagnosis, prognosis, and treatment. Radiomics, a quantitative image analysis technique, extracts a wealth of information from medical images, providing insights into tumor biology and response to therapy. Molecular biology, on the other hand, focuses on understanding the genetic and molecular alterations underlying tumorigenesis. By integrating radiomics and molecular biology, researchers aim to develop more accurate prognostic biomarkers, optimize treatment strategies, and ultimately improve patient outcomes. This Special Issue will delve into the current state of the art in radiomics and molecular biology for glioma, exploring their synergistic potential in advancing personalized medicine.

---

### Guest Editors

Dr. Anna Luisa Di Stefano

Division of Neurosurgery, Spedali Riuniti di Livorno—USL Toscana Nord-Ovest, 57124 Livorno, Italy

Dr. Gianluca Grimod

Division of Neurosurgery, Policlinico San Matteo Pavia, Viale Camillo Golgi, 19, 27100 Pavia, Italy

---

### Deadline for manuscript submissions

closed (15 October 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/222827](https://mdpi.com/si/222827)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)